IP Group plc – Appointment of Aedhmar Hynes as Non-executive Director

IP Group PLC

IP Group plc (LON: IPO), the developer of intellectual property-based businesses, has today announced the appointment of Aedhmar Hynes as an independent Non-executive Director with effect from 1 August 2019.

Ms. Hynes was Chief Executive Officer of Text100, a digital communications agency with 22 offices and over 600 consultants across Europe, North America and Asia. Through her consulting work she has advised and supported many of the world’s most important brands through digital transformation and technology disruption.

Ranked among the 50 most powerful communications professionals in the world, according to PRWeek, she is Chairman of the Board of Trustees of The Page Society, the preeminent industry body for Chief Communications Officers of Fortune 500 companies. In 2016, she was appointed to the Advisory Council of the MIT Media Lab, a leading technology research institute addressing many of the world’s biggest challenges. She also serves as a Board Director of Technoserve, helping entrepreneurs emerge from poverty in the developing world. She is on the US Foundation Board of the National University of Ireland, Galway and is a Henry Crown Fellow at The Aspen Institute.

Sir Douglas Flint, Chairman of IP Group, said:

“Aedhmar adds fresh and valuable experience to the Board around technology disruption, digital transformation and marketing and strategic communications. She also brings the knowledge gained from having overseen and led the growth of a business to become a leading global network. I’m delighted to welcome Aedhmar to the Board and we are looking forward to working with her.”

Share on:

Latest Company News

IP Group portfolio company Istesso begins Phase 2 trial of leramistat

Istesso has started dosing in a Phase 2 trial of leramistat in rheumatoid arthritis-related sarcopenia, evaluating its effects on muscle quality, repair and function.

IP Group’s New Chair Designate Signals Confidence in Long Term Growth, Equity Development

IP Group appoints former 3i CEO Michael Queen as Chair Designate as Equity Development highlights significant NAV discount potential.

IP Group sees revenue potential from Metsera obesity drug deal

IP Group plc has outlined potential future revenue opportunities from obesity drug candidates developed by Metsera, following Pfizer’s agreement to acquire Metsera for up to $7.3 billion.

IP Group Plc two quoted life sciences portfolio companies receive cash offers

IP Group plc celebrates cash offers for life sciences portfolio firms, expecting significant returns to fuel further investment and share buybacks.

    Search